Elizabeth McFarland
Concepts (399)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 53 | 2026 | 3210 | 3.140 |
Why?
| | HIV-1 | 28 | 2026 | 911 | 2.840 |
Why?
| | Respiratory Syncytial Virus Vaccines | 6 | 2022 | 39 | 2.190 |
Why?
| | HIV Antibodies | 14 | 2026 | 61 | 2.190 |
Why?
| | Respiratory Syncytial Virus Infections | 6 | 2022 | 139 | 2.000 |
Why?
| | Respiratory Syncytial Virus, Human | 6 | 2022 | 81 | 1.990 |
Why?
| | Infectious Disease Transmission, Vertical | 18 | 2025 | 188 | 1.970 |
Why?
| | Anti-HIV Agents | 15 | 2026 | 914 | 1.690 |
Why?
| | Anti-Retroviral Agents | 12 | 2023 | 250 | 1.620 |
Why?
| | Viral Proteins | 3 | 2020 | 350 | 1.470 |
Why?
| | Antibodies, Neutralizing | 10 | 2026 | 346 | 1.100 |
Why?
| | Antibodies, Viral | 8 | 2022 | 683 | 1.050 |
Why?
| | Antibodies, Monoclonal | 7 | 2026 | 1511 | 0.940 |
Why?
| | Colonography, Computed Tomographic | 3 | 2024 | 8 | 0.910 |
Why?
| | Pregnancy Complications, Infectious | 9 | 2026 | 437 | 0.870 |
Why?
| | HIV Protease Inhibitors | 3 | 2026 | 69 | 0.810 |
Why?
| | AIDS Vaccines | 8 | 2018 | 53 | 0.800 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2025 | 272 | 0.710 |
Why?
| | Gene Deletion | 2 | 2020 | 384 | 0.690 |
Why?
| | Breast Feeding | 4 | 2025 | 447 | 0.610 |
Why?
| | Atazanavir Sulfate | 2 | 2017 | 41 | 0.600 |
Why?
| | Ritonavir | 2 | 2017 | 75 | 0.580 |
Why?
| | Infant, Newborn | 24 | 2026 | 6449 | 0.550 |
Why?
| | HIV Envelope Protein gp120 | 6 | 2017 | 55 | 0.540 |
Why?
| | Vaccination | 6 | 2020 | 1444 | 0.540 |
Why?
| | Vaccines, Attenuated | 6 | 2022 | 129 | 0.540 |
Why?
| | Infant | 34 | 2026 | 10093 | 0.530 |
Why?
| | Incidental Findings | 1 | 2018 | 81 | 0.510 |
Why?
| | Radiation Dosage | 1 | 2018 | 193 | 0.480 |
Why?
| | Nelfinavir | 1 | 2016 | 7 | 0.480 |
Why?
| | Telemedicine | 1 | 2025 | 956 | 0.470 |
Why?
| | Lopinavir | 1 | 2016 | 30 | 0.470 |
Why?
| | Syncope | 1 | 2016 | 48 | 0.470 |
Why?
| | Patient Dropouts | 1 | 2016 | 65 | 0.460 |
Why?
| | Bradycardia | 1 | 2016 | 63 | 0.460 |
Why?
| | Lyme Disease | 1 | 2016 | 58 | 0.450 |
Why?
| | Health Resources | 1 | 2016 | 130 | 0.430 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 113 | 0.420 |
Why?
| | HIV | 5 | 2014 | 249 | 0.390 |
Why?
| | Child | 40 | 2026 | 22638 | 0.390 |
Why?
| | Humans | 80 | 2026 | 145625 | 0.390 |
Why?
| | Patient Compliance | 2 | 2018 | 587 | 0.370 |
Why?
| | Female | 54 | 2026 | 79080 | 0.370 |
Why?
| | Immunogenicity, Vaccine | 4 | 2021 | 40 | 0.350 |
Why?
| | Adolescent | 30 | 2026 | 22451 | 0.340 |
Why?
| | Male | 45 | 2026 | 73014 | 0.340 |
Why?
| | Referral and Consultation | 1 | 2018 | 878 | 0.340 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2005 | 180 | 0.330 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 1148 | 0.330 |
Why?
| | Virus Replication | 4 | 2020 | 525 | 0.330 |
Why?
| | Viral Load | 10 | 2026 | 525 | 0.310 |
Why?
| | Lymphocyte Activation | 5 | 2017 | 1136 | 0.300 |
Why?
| | Young Adult | 15 | 2026 | 14240 | 0.290 |
Why?
| | DNA, Viral | 3 | 2026 | 352 | 0.260 |
Why?
| | HIV Seropositivity | 2 | 2023 | 117 | 0.260 |
Why?
| | Bone Density | 2 | 2025 | 492 | 0.260 |
Why?
| | Double-Blind Method | 3 | 2020 | 2064 | 0.240 |
Why?
| | RNA, Viral | 8 | 2023 | 691 | 0.230 |
Why?
| | Antibodies, Bacterial | 2 | 2018 | 147 | 0.230 |
Why?
| | Child, Preschool | 23 | 2026 | 11888 | 0.220 |
Why?
| | Antiretroviral Therapy, Highly Active | 6 | 2017 | 278 | 0.220 |
Why?
| | Dyslipidemias | 2 | 2017 | 184 | 0.220 |
Why?
| | Bone Development | 1 | 2025 | 52 | 0.220 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2026 | 662 | 0.220 |
Why?
| | Puberty | 1 | 2026 | 141 | 0.210 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 196 | 0.210 |
Why?
| | Pregnancy | 12 | 2026 | 7217 | 0.210 |
Why?
| | Immunoglobulin G | 3 | 2022 | 899 | 0.210 |
Why?
| | Viremia | 3 | 2011 | 158 | 0.200 |
Why?
| | Diverticulum | 1 | 2024 | 14 | 0.200 |
Why?
| | Gene Products, gag | 2 | 1994 | 38 | 0.200 |
Why?
| | Mammography | 1 | 2025 | 172 | 0.190 |
Why?
| | Squalene | 3 | 2017 | 9 | 0.190 |
Why?
| | Complementarity Determining Regions | 1 | 2002 | 54 | 0.180 |
Why?
| | Prospective Studies | 5 | 2025 | 8087 | 0.180 |
Why?
| | Drug Resistance, Viral | 2 | 2016 | 126 | 0.180 |
Why?
| | CD4 Lymphocyte Count | 4 | 2017 | 280 | 0.170 |
Why?
| | Half-Life | 1 | 2021 | 157 | 0.170 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2021 | 44 | 0.170 |
Why?
| | Immunization Schedule | 2 | 2018 | 186 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2025 | 1125 | 0.170 |
Why?
| | Mitochondrial Diseases | 1 | 2021 | 94 | 0.160 |
Why?
| | Colorado | 4 | 2025 | 4588 | 0.160 |
Why?
| | Drug Therapy, Combination | 4 | 2017 | 1034 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 330 | 0.160 |
Why?
| | T-Lymphocytes | 2 | 2009 | 2007 | 0.160 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 187 | 0.160 |
Why?
| | RNA, Small Untranslated | 1 | 2020 | 14 | 0.160 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 2 | 2017 | 15 | 0.150 |
Why?
| | Pilot Projects | 1 | 2025 | 1878 | 0.150 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 193 | 0.150 |
Why?
| | Cytokines | 2 | 2021 | 2079 | 0.150 |
Why?
| | Point Mutation | 1 | 2020 | 232 | 0.140 |
Why?
| | Body Temperature | 1 | 2020 | 227 | 0.140 |
Why?
| | Immunocompromised Host | 2 | 2000 | 201 | 0.140 |
Why?
| | Haemophilus Vaccines | 2 | 2018 | 29 | 0.140 |
Why?
| | Insulin Resistance | 3 | 2019 | 1247 | 0.140 |
Why?
| | Immunologic Memory | 2 | 2021 | 369 | 0.140 |
Why?
| | Interleukin-12 | 1 | 1998 | 115 | 0.130 |
Why?
| | Adult | 18 | 2026 | 40821 | 0.130 |
Why?
| | Darunavir | 1 | 2017 | 20 | 0.130 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 339 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2011 | 929 | 0.130 |
Why?
| | Metabolic Syndrome | 1 | 2021 | 364 | 0.130 |
Why?
| | Vinyl Chloride | 1 | 2017 | 2 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2018 | 0.130 |
Why?
| | Therapeutic Equipoise | 1 | 2017 | 1 | 0.130 |
Why?
| | Interferon-gamma | 5 | 2012 | 780 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 290 | 0.120 |
Why?
| | Immunoglobulin A | 2 | 2017 | 205 | 0.120 |
Why?
| | Lymphopoiesis | 1 | 2017 | 27 | 0.120 |
Why?
| | Uganda | 1 | 2017 | 91 | 0.120 |
Why?
| | Receptors, CCR5 | 1 | 2017 | 59 | 0.120 |
Why?
| | CD4-CD8 Ratio | 1 | 2016 | 23 | 0.120 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
| | Mass Casualty Incidents | 1 | 2017 | 52 | 0.120 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 179 | 0.120 |
Why?
| | Adoption | 1 | 2016 | 25 | 0.120 |
Why?
| | Mothers | 3 | 2017 | 771 | 0.120 |
Why?
| | Virus Latency | 1 | 2016 | 93 | 0.110 |
Why?
| | Cohort Studies | 8 | 2025 | 6045 | 0.110 |
Why?
| | Early Diagnosis | 1 | 2016 | 249 | 0.110 |
Why?
| | Chickenpox Vaccine | 1 | 2015 | 75 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2018 | 297 | 0.110 |
Why?
| | Disease Susceptibility | 1 | 2017 | 339 | 0.110 |
Why?
| | Zimbabwe | 2 | 2025 | 76 | 0.110 |
Why?
| | Body Height | 2 | 2017 | 202 | 0.110 |
Why?
| | Gene Products, env | 1 | 1994 | 7 | 0.110 |
Why?
| | Haemophilus influenzae type b | 1 | 2014 | 12 | 0.110 |
Why?
| | Chickenpox | 1 | 2015 | 83 | 0.110 |
Why?
| | Bacterial Capsules | 1 | 2014 | 33 | 0.110 |
Why?
| | Antibody Affinity | 1 | 2014 | 60 | 0.110 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2000 | 237 | 0.100 |
Why?
| | Cote d'Ivoire | 2 | 2025 | 9 | 0.100 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.100 |
Why?
| | Vaccines, Synthetic | 4 | 2005 | 138 | 0.100 |
Why?
| | Developing Countries | 1 | 2016 | 312 | 0.100 |
Why?
| | South Africa | 2 | 2025 | 262 | 0.100 |
Why?
| | Intestines | 1 | 2017 | 351 | 0.100 |
Why?
| | Puberty, Delayed | 1 | 2013 | 10 | 0.100 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2002 | 224 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 4 | 2013 | 585 | 0.100 |
Why?
| | Vaccines | 1 | 2018 | 389 | 0.100 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1993 | 34 | 0.100 |
Why?
| | Mycobacterium chelonae | 1 | 1993 | 8 | 0.100 |
Why?
| | Injections, Subcutaneous | 2 | 2026 | 170 | 0.100 |
Why?
| | United States | 10 | 2026 | 16041 | 0.090 |
Why?
| | Patient Selection | 1 | 2017 | 720 | 0.090 |
Why?
| | Lamivudine | 3 | 2023 | 63 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2023 | 17291 | 0.090 |
Why?
| | Lipids | 1 | 2017 | 715 | 0.090 |
Why?
| | Cell Movement | 1 | 2017 | 950 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 870 | 0.090 |
Why?
| | Child Development | 1 | 2017 | 481 | 0.090 |
Why?
| | Mitochondria | 2 | 2021 | 996 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2411 | 0.090 |
Why?
| | STAT1 Transcription Factor | 1 | 2012 | 68 | 0.090 |
Why?
| | Body Weight | 2 | 2017 | 964 | 0.090 |
Why?
| | Cardiovascular Diseases | 2 | 2016 | 2218 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2019 | 635 | 0.090 |
Why?
| | Body Fat Distribution | 1 | 2011 | 46 | 0.090 |
Why?
| | Polysorbates | 3 | 2017 | 42 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1062 | 0.090 |
Why?
| | Mycobacterium avium Complex | 1 | 2012 | 87 | 0.080 |
Why?
| | Epitopes | 2 | 2022 | 479 | 0.080 |
Why?
| | Cost-Benefit Analysis | 2 | 2025 | 632 | 0.080 |
Why?
| | Research Design | 1 | 2017 | 1139 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 724 | 0.080 |
Why?
| | Interleukin-2 | 2 | 2003 | 434 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2017 | 680 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 399 | 0.070 |
Why?
| | Freezing | 1 | 2009 | 84 | 0.070 |
Why?
| | Absorptiometry, Photon | 2 | 2025 | 276 | 0.070 |
Why?
| | Exercise | 1 | 2021 | 2206 | 0.070 |
Why?
| | Blood | 1 | 2009 | 107 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3186 | 0.070 |
Why?
| | Algorithms | 1 | 2016 | 1843 | 0.070 |
Why?
| | Age Factors | 4 | 2019 | 3321 | 0.070 |
Why?
| | T-Lymphocyte Subsets | 2 | 2002 | 415 | 0.070 |
Why?
| | Staff Development | 1 | 2009 | 62 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2009 | 79 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 845 | 0.070 |
Why?
| | Biomarkers | 4 | 2021 | 4329 | 0.070 |
Why?
| | Specimen Handling | 1 | 2009 | 178 | 0.060 |
Why?
| | Enterovirus A, Human | 1 | 2007 | 13 | 0.060 |
Why?
| | Longitudinal Studies | 3 | 2025 | 3005 | 0.060 |
Why?
| | Faculty | 1 | 2009 | 151 | 0.060 |
Why?
| | Withholding Treatment | 1 | 2008 | 77 | 0.060 |
Why?
| | Adipose Tissue | 1 | 2011 | 641 | 0.060 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2007 | 78 | 0.060 |
Why?
| | Polymerase Chain Reaction | 4 | 2011 | 1030 | 0.060 |
Why?
| | Puerto Rico | 1 | 2026 | 64 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2009 | 1160 | 0.060 |
Why?
| | Monte Carlo Method | 1 | 2026 | 150 | 0.060 |
Why?
| | Academic Medical Centers | 1 | 2009 | 560 | 0.060 |
Why?
| | False Negative Reactions | 1 | 2025 | 61 | 0.050 |
Why?
| | Cell Line | 3 | 2012 | 2809 | 0.050 |
Why?
| | Enterovirus Infections | 1 | 2007 | 175 | 0.050 |
Why?
| | Isoantigens | 1 | 1984 | 17 | 0.050 |
Why?
| | C-Reactive Protein | 2 | 2021 | 427 | 0.050 |
Why?
| | Medical Audit | 1 | 2025 | 77 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2006 | 277 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 847 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2007 | 420 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2007 | 771 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5397 | 0.050 |
Why?
| | Confusion | 1 | 2024 | 30 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1652 | 0.050 |
Why?
| | Thymus Gland | 1 | 1984 | 310 | 0.050 |
Why?
| | Hospitalization | 2 | 2026 | 2468 | 0.050 |
Why?
| | Tablets | 1 | 2023 | 41 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 238 | 0.050 |
Why?
| | Regression Analysis | 2 | 2021 | 994 | 0.050 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2022 | 58 | 0.050 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 22 | 0.050 |
Why?
| | Risk Factors | 4 | 2021 | 10840 | 0.050 |
Why?
| | Immunophenotyping | 2 | 1994 | 324 | 0.050 |
Why?
| | Zidovudine | 2 | 2015 | 75 | 0.050 |
Why?
| | Clone Cells | 1 | 2002 | 259 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2001 | 77 | 0.040 |
Why?
| | Cough | 1 | 2022 | 123 | 0.040 |
Why?
| | Emtricitabine | 1 | 2023 | 209 | 0.040 |
Why?
| | Triazoles | 1 | 2023 | 190 | 0.040 |
Why?
| | Vaccines, Subunit | 1 | 2001 | 53 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 49 | 0.040 |
Why?
| | Pyridones | 1 | 2023 | 210 | 0.040 |
Why?
| | Ganciclovir | 1 | 2000 | 51 | 0.040 |
Why?
| | Tenofovir | 1 | 2023 | 300 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 84 | 0.040 |
Why?
| | Lung | 1 | 2014 | 4119 | 0.040 |
Why?
| | Computer Simulation | 1 | 2005 | 1014 | 0.040 |
Why?
| | Africa | 1 | 2020 | 119 | 0.040 |
Why?
| | Adjuvants, Immunologic | 2 | 2017 | 243 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2021 | 108 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 137 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 2101 | 0.040 |
Why?
| | HIV Seronegativity | 1 | 2019 | 28 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5875 | 0.040 |
Why?
| | HLA-D Antigens | 1 | 1999 | 30 | 0.040 |
Why?
| | Risk | 1 | 2021 | 917 | 0.040 |
Why?
| | Incidence | 1 | 2026 | 2910 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3633 | 0.040 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1998 | 49 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 2000 | 203 | 0.030 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1998 | 39 | 0.030 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 28 | 0.030 |
Why?
| | Vaccines, Combined | 1 | 2018 | 49 | 0.030 |
Why?
| | Prevalence | 2 | 2016 | 2852 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2019 | 201 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2088 | 0.030 |
Why?
| | Hospitals | 1 | 2023 | 730 | 0.030 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2018 | 27 | 0.030 |
Why?
| | Odds Ratio | 1 | 2021 | 1070 | 0.030 |
Why?
| | Hepatitis B Vaccines | 1 | 2018 | 43 | 0.030 |
Why?
| | Mutation | 3 | 2018 | 4082 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2835 | 0.030 |
Why?
| | Drug Resistance, Microbial | 2 | 2000 | 67 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2019 | 270 | 0.030 |
Why?
| | Colon | 1 | 2020 | 304 | 0.030 |
Why?
| | Case Management | 1 | 2018 | 66 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1998 | 186 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 2019 | 363 | 0.030 |
Why?
| | New Jersey | 1 | 2017 | 17 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 410 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1998 | 175 | 0.030 |
Why?
| | Treatment Adherence and Compliance | 1 | 2017 | 27 | 0.030 |
Why?
| | Immune Tolerance | 1 | 1999 | 384 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 527 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 649 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3396 | 0.030 |
Why?
| | Cell Division | 1 | 1998 | 735 | 0.030 |
Why?
| | Emergency Responders | 1 | 2017 | 38 | 0.030 |
Why?
| | Lymphocyte Count | 2 | 2009 | 166 | 0.030 |
Why?
| | Middle Aged | 4 | 2026 | 36359 | 0.030 |
Why?
| | Treatment Failure | 1 | 2017 | 358 | 0.030 |
Why?
| | Uncertainty | 1 | 2017 | 145 | 0.030 |
Why?
| | Disaster Planning | 1 | 2017 | 109 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 17 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2015 | 169 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 413 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 128 | 0.030 |
Why?
| | Maternal Exposure | 1 | 2017 | 189 | 0.030 |
Why?
| | Genes, pol | 1 | 1994 | 7 | 0.030 |
Why?
| | Malnutrition | 1 | 2016 | 86 | 0.030 |
Why?
| | Vaccines, Conjugate | 1 | 2014 | 60 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2000 | 774 | 0.030 |
Why?
| | Coinfection | 1 | 2016 | 143 | 0.030 |
Why?
| | Counseling | 1 | 2018 | 403 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 153 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2017 | 257 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1754 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2021 | 11744 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2008 | 4112 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 402 | 0.020 |
Why?
| | Anemia | 1 | 2015 | 189 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 171 | 0.020 |
Why?
| | Electron Transport Complex IV | 1 | 2013 | 61 | 0.020 |
Why?
| | Electron Transport Complex I | 1 | 2013 | 42 | 0.020 |
Why?
| | Sexual and Gender Minorities | 1 | 2018 | 268 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2015 | 205 | 0.020 |
Why?
| | Tuberculosis, Cutaneous | 1 | 1993 | 2 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 1993 | 32 | 0.020 |
Why?
| | CD8 Antigens | 1 | 1993 | 70 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 174 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2910 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 535 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2008 | 782 | 0.020 |
Why?
| | CD3 Complex | 1 | 1993 | 112 | 0.020 |
Why?
| | Lymphocytes | 1 | 1994 | 379 | 0.020 |
Why?
| | Blood Pressure | 1 | 2019 | 1761 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2013 | 212 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 212 | 0.020 |
Why?
| | P-Selectin | 1 | 2011 | 29 | 0.020 |
Why?
| | Tuberculosis, Pulmonary | 1 | 1993 | 127 | 0.020 |
Why?
| | E-Selectin | 1 | 2011 | 61 | 0.020 |
Why?
| | Heteroduplex Analysis | 1 | 2011 | 1 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 112 | 0.020 |
Why?
| | Blood Transfusion | 1 | 1994 | 393 | 0.020 |
Why?
| | Antigens, CD | 1 | 1994 | 559 | 0.020 |
Why?
| | Cell Proliferation | 2 | 2009 | 2497 | 0.020 |
Why?
| | Nontuberculous Mycobacteria | 1 | 1993 | 189 | 0.020 |
Why?
| | Hyperlipidemias | 1 | 2011 | 120 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 201 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2012 | 201 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2011 | 180 | 0.020 |
Why?
| | Fibrinogen | 1 | 2011 | 181 | 0.020 |
Why?
| | Communication | 1 | 2017 | 979 | 0.020 |
Why?
| | Health Personnel | 1 | 2017 | 750 | 0.020 |
Why?
| | Cross Infection | 1 | 1993 | 258 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2017 | 728 | 0.020 |
Why?
| | Infant, Premature | 1 | 1994 | 622 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1500 | 0.020 |
Why?
| | Pokeweed Mitogens | 1 | 2009 | 6 | 0.020 |
Why?
| | Human Experimentation | 1 | 2009 | 12 | 0.020 |
Why?
| | L-Selectin | 1 | 2009 | 27 | 0.020 |
Why?
| | Tetanus | 1 | 2009 | 29 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2009 | 86 | 0.020 |
Why?
| | Candida | 1 | 2009 | 46 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1531 | 0.020 |
Why?
| | Meningitis, Aseptic | 1 | 2007 | 13 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3123 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2007 | 31 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1717 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 782 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 365 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2007 | 88 | 0.020 |
Why?
| | Paralysis | 1 | 2007 | 69 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2007 | 122 | 0.020 |
Why?
| | Kinetics | 1 | 2010 | 1553 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2012 | 884 | 0.010 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 502 | 0.010 |
Why?
| | Respiratory System | 1 | 2007 | 150 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1866 | 0.010 |
Why?
| | Immunoglobulin A, Secretory | 1 | 2005 | 8 | 0.010 |
Why?
| | Cell Survival | 1 | 2009 | 1102 | 0.010 |
Why?
| | Phosphates | 1 | 1987 | 175 | 0.010 |
Why?
| | Muscles | 1 | 1987 | 330 | 0.010 |
Why?
| | Encephalitis | 1 | 2007 | 142 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2007 | 203 | 0.010 |
Why?
| | Mucous Membrane | 1 | 2005 | 129 | 0.010 |
Why?
| | Chemistry, Physical | 1 | 1984 | 36 | 0.010 |
Why?
| | Antigen-Antibody Reactions | 1 | 1984 | 50 | 0.010 |
Why?
| | Chemical Phenomena | 1 | 1984 | 75 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2357 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1467 | 0.010 |
Why?
| | Myasthenia Gravis | 1 | 1984 | 24 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1984 | 69 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1984 | 334 | 0.010 |
Why?
| | Saliva | 1 | 2005 | 256 | 0.010 |
Why?
| | Epithelium | 1 | 1984 | 295 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2766 | 0.010 |
Why?
| | Aging | 2 | 2003 | 1983 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 2357 | 0.010 |
Why?
| | Body Mass Index | 1 | 2011 | 2446 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 429 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 787 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1993 | 1935 | 0.010 |
Why?
| | Aged | 2 | 2017 | 26251 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1244 | 0.010 |
Why?
| | Suspensions | 1 | 2000 | 28 | 0.010 |
Why?
| | Capsules | 1 | 2000 | 40 | 0.010 |
Why?
| | Drug Tolerance | 1 | 2000 | 99 | 0.010 |
Why?
| | Urban Population | 1 | 2003 | 496 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 169 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5234 | 0.010 |
Why?
| | Immunization | 1 | 2000 | 375 | 0.010 |
Why?
| | Epithelial Cells | 1 | 1984 | 1118 | 0.010 |
Why?
| | Administration, Oral | 1 | 2000 | 867 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 7079 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2000 | 1361 | 0.010 |
Why?
| | Macrophages | 1 | 1984 | 1530 | 0.010 |
Why?
| | Tail | 1 | 1987 | 28 | 0.000 |
Why?
| | Phosphocreatine | 1 | 1987 | 44 | 0.000 |
Why?
| | Mice | 1 | 1984 | 18266 | 0.000 |
Why?
| | Salamandridae | 1 | 1987 | 33 | 0.000 |
Why?
| | Animals | 2 | 1987 | 38030 | 0.000 |
Why?
| | Adenosine Triphosphate | 1 | 1987 | 494 | 0.000 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1987 | 627 | 0.000 |
Why?
|
|
McFarland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|